Baxter International Inc. (BAX) Q3 2026 Earnings Call Transcript

Baxter International Inc. (BAX) Q3 2026 Earnings Call Transcript

Seeking Alpha • 8 hours ago

Baxter Reports Third-Quarter 2026 Results

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2026. “We delivered a strong third quarter, with growth across all segments and divisions globally,” said Andrew Hider, president and CEO. “We continue to make steady progress stabilizing the business, strengthening the balance sheet and driving continuous improvement. Our results reinforce our confidence in this direction as we build a stronger founda.

Business Wire • 14 hours ago

Why Is Baxter Stock Trading Lower on Thursday?

Baxter International Inc. (NYSE:BAX) on Thursday reported better-than-expected third-quarter financial results and raised its fiscal 2026 guidance.

Benzinga • 9 hours ago

Baxter International (BAX) Q3 Earnings and Revenues Surpass Estimates

Baxter International (BAX) came out with quarterly earnings of $0.58 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.69 per share a year ago.

Zacks Investment Research • 11 hours ago

Compared to Estimates, Baxter (BAX) Q3 Earnings: A Look at Key Metrics

The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • 10 hours ago

Baxter Q3 Earnings Beat on Broad-Based Growth, '26 Outlook Raised

BAX beats Q3 earnings and revenue estimates, driven by broad-based segment growth, and raises its 2026 outlook despite continued margin pressure.

Zacks Investment Research • 8 hours ago

Will Baxter's Q3 Earnings Show Progress Despite Cost Pressures?

Baxter International Inc. BAX is scheduled to release third-quarter 2026 results on Oct. 29, before the opening bell. In the last reported quarter, the company's earnings beat the Zacks Consensus Estimate by 55.6%.

Zacks Investment Research • Oct 26, 2026

Analysts Estimate Baxter International (BAX) to Report a Decline in Earnings: What to Look Out for

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 22, 2026

Baxter International: The Vantive Transition Complicates Margin Recovery

Baxter International is rated Hold, with a $25 target price and limited 2.6% upside, reflecting muted near-term margin recovery. Revenue growth is supported by Advanced Surgery and compounding, but infusion solutions face structural headwinds, and Novum IQ LVP supply issues persist. Margins lag revenue growth; cost reductions and inventory normalization may help, but transition expenses and debt reduction remain priorities through 2027.

Seeking Alpha • Oct 13, 2026

Baxter to Host Third-Quarter 2026 Financial Results Conference Call for Investors

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2026 financial results on Thursday, October 29, 2026, at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://events.q4inc.com/analyst/129835310?pwd=2FG2j7ZZ to pre-register for the call and receive the call information.This call is also being webcast and can be accessed through Baxter's website at www.

Business Wire • Oct 7, 2026